The use of erlotinib was not effective in inhibiting KRAS mutated NSCLC tumors, and the heterogeneous biology of KRAS mutant NSCLC tumors [6] explains the failure of the BATTLE-2 study. Here, KRAS is linked to non-small cell lung carcinoma.